Pharmaceutica Analytica Acta

Drug loaded in situ hydrogels for rheumatoid arthritis treatment

8^th International Conference and Exhibition on Pharmaceutics & Novel Drug Delivery Systems

March 07-09, 2016 Madrid, Spain

N Storozhylova, J Crecente-Campo, C Grandjean and M J Alonso

University of Santiago de Compostela, Spain Universite de Nantes, France

Posters & Accepted Abstracts: Pharm Anal Acta

Abstract:

Galectin-3 (Gal-3) is a human protein able to bind sugar β-galactoside motifs and devoid of enzymatic activity. Extracellular Gal-3 was found to control and participate in immune and inflammatory responses, favouring macrophage pro-inflammatory cytokine secretion and involved in cartilage remodeling and bone erosion. It is believed that extracellular Gal-3 inhibition is a potential strategy for rheumatoid arthritis (RA) treatment and it can present a platform for the development of a new therapy approach. Previously, we reported the synthesis of Gal-3 inhibitors as anti-RA drugs. Here, we describe the formulation of this potential drug in a delivery system that is adequate for intra-articular injection. The delivery system consist of hyaluronic acid (HA) constructs containing Gal-3 inhibitor, dispersed in a modified HA hydrogel. The constructsâ?? parameters allow them to stay invisible for macrophages and target specifically extracellular Gal-3. Hydrogels form in situ after the injection of components solution and have well defined and controlled gellation time of 2 min. Their porous structure is sufficient for maintaining the Gal-3 inhibitor constructs. Maximal loading of them to in situ hydrogels is 30% with the gellation time of 20 min.

Biography :

N Storozhylova is an Erasmus Mundus NanoFar PhD student at University of Nantes and University of Santiago de Compostela, 2013-2016.

Email: Nstorozhylova@gmail.com